News
One article a week on retatrutide, GLP-1 medicines and peptide research, with UK regulation first. Every article links to its sources.
30 September 2026
Nordic registry study finds no link between semaglutide and pancreatic cancer
A manufacturer-funded registry study from Denmark, Sweden and Norway, presented at EASD 2026, found no link between semaglutide and pancreatic cancer.
30 September 2026
TRIUMPH-2: full retatrutide results in type 2 diabetes published in The Lancet
Full TRIUMPH-2 results for retatrutide in people with obesity and type 2 diabetes were presented at EASD and published in The Lancet. What the data show.